See the DrugPatentWatch profile for nucala
Is GSK’s Nucala “composition of matter” patent actually set to expire in 2029?
Based on the information you provided, yes: GSK’s Nucala “composition of matter” patent is described as expiring in 2029. That date would typically be the anchor for when generic or biosimilar competitors can pursue market entry, assuming no other legal or regulatory barriers delay it.
What does “composition of matter” patent expiry in 2029 mean for Nucala?
A composition of matter patent covers the protected drug substance (the core molecular entity) rather than a specific formulation, method of use, or dosing schedule. When that patent expires, competitors may be able to use the protected active ingredient legally for their own product development, subject to:
- Remaining method-of-use or formulation patents that might still be in force
- Patent litigation outcomes (invalidation findings, settlement terms, or continuing injunctions)
- Regulatory exclusivities that can delay approval or launch even after patent expiry
Could other patents extend exclusivity beyond 2029?
Even if the composition of matter patent ends in 2029, other layers of protection can still matter. These commonly include additional patents around:
- Specific indications (method-of-use)
- Formulations or delivery (if applicable)
- Related manufacturing processes
- Patient selection or treatment regimens
How does this affect biosimilars vs generics for Nucala?
Nucala is a biologic (mepolizumab). That generally means the relevant market challenge is usually biosimilars rather than traditional small-molecule generics. Patent expiry in 2029 is still important, but actual entry timing often depends on whether a biosimilar applicant can get approval and whether any remaining patents or exclusivities block commercialization.
When would competitors likely launch after a 2029 expiry?
Actual launch timing usually follows the combination of:
- Patent status at the time of the expiry date (including any litigation)
- Ability to file and get regulatory approval for a biosimilar
- Any exclusivity protections that persist after patent expiry
So while 2029 is the key date you cited, the first commercial entry could be later depending on those factors.
What should you check to confirm the exact 2029 date?
To verify the “composition of matter” expiry and how it translates into real-world entry risk, you would typically confirm:
- The specific patent number(s) and expiry date on GSK’s patent listings or relevant patent databases
- Whether any additional patents are listed for Nucala in the same jurisdiction
- Whether there is pending litigation or an agreed “carve-out”/entry date in settlements
What happens if the 2029 date is wrong or changes?
If the expiry date is challenged, stayed, extended (via adjustments), or replaced by a new patent family covering a different claim, it can move the timeline. Courts can also affect how and whether other patents block entry.
If you share the patent number (or the country/jurisdiction) tied to the “composition of matter” claim, I can help interpret what the 2029 expiry likely means for biosimilar entry and what other protections are most likely to still be in play.